Department of Pathology, University Hospital, Jihlavska 20, 625 00 Brno, Czech Republic.
Neoplasma. 2012;59(6):606-12. doi: 10.4149/neo_2012_077.
Roscovitine, an inhibitor of cyclin-dependent kinases, is promising anticancer agent. Its antiproliferative and cytotoxic effects can be mediated by the p53 signaling pathway. To define the role of p53 in roscovitine-induced cell response, we prepared H1299/p53 cell lines inducibly expressing specific variants of p53 (p53wt and hotspot R175H, temperature-dependent P98A, A159V, S215G, Y220C, Y234C mutants). In the presence of roscovitine, each cell line variant behaved in specific way reflecting activity of the p53 protein. Roscovitine decreased production of the cell cycle inhibitor p21 and induced apoptosis. This effect was the most efficient in cells expressing p53wt protein with full activity. The cell expressing partially and conditionally active p53 mutants responded to roscovitine less efficiently. The cells expressing p53 mutants A159V and Y234C were very sensitive to roscovitine but their response was clearly temperature-dependent. The cells expressing P98A, S215G and Y220C p53 mutants exhibited only weak sensitivity to roscovitine and underwent apoptosis in low frequency. In principle, each td p53 mutant responded to roscovitine in distinct way. We showed clearly that the impact of roscovitine on H1299 cells depends on functional status of p53 they produce. This suggests that patients with tumors exhibiting specific p53 variants can benefit from the roscovitine therapy.
罗沙司他是一种细胞周期依赖性激酶抑制剂,是一种很有前途的抗癌药物。其抗增殖和细胞毒性作用可以通过 p53 信号通路介导。为了确定 p53 在罗沙司他诱导的细胞反应中的作用,我们制备了可诱导表达特定 p53 变体(野生型 p53 和热点 R175H、温度依赖性 P98A、A159V、S215G、Y220C、Y234C 突变体)的 H1299/p53 细胞系。在罗沙司他存在的情况下,每种细胞系变体的行为都以反映 p53 蛋白活性的特定方式表现出来。罗沙司他降低了细胞周期抑制剂 p21 的产生并诱导了细胞凋亡。这种作用在具有完全活性的野生型 p53 蛋白表达的细胞中最为有效。部分和条件性激活的 p53 突变体表达的细胞对罗沙司他的反应效率较低。表达 p53 突变体 A159V 和 Y234C 的细胞对罗沙司他非常敏感,但它们的反应明显依赖于温度。表达 P98A、S215G 和 Y220C p53 突变体的细胞对罗沙司他仅表现出较弱的敏感性,并以较低的频率发生细胞凋亡。原则上,每种 td p53 突变体对罗沙司他的反应方式都不同。我们清楚地表明,罗沙司他对 H1299 细胞的影响取决于它们产生的功能性 p53 状态。这表明,具有特定 p53 变体的肿瘤患者可以从罗沙司他治疗中受益。